Verily Secures $300 Million Investment and Gains Independence from Alphabet to Advance AI-Driven Precision Health Platform
核心洞察
Verily Health Inc. (搜索) raised $300 million in Series X Capital (搜索)-led funding, with Alphabet (搜索) relinquishing its controlling stake while remaining a significant minority investor.
The company restructured from an LLC to an independent corporation, gaining neutrality needed for healthcare industry partnerships and data sharing collaborations.
Verily's AI-native precision health platform includes the Pre platform for clinical research acceleration and Lightpath for chronic disease management.
Verily Life Sciences has secured $300 million in funding and restructured as an independent corporation, marking a pivotal transition from Alphabet (搜索) subsidiary to standalone precision health company. The investment round, led by Series X Capital (搜索) with participation from Alphabet, UCHealth, and the University of Colorado Anschutz (搜索), enables the company to accelerate its AI-native precision health platform strategy while gaining critical independence from its former parent.
Corporate Restructuring Creates Strategic Independence
The funding coincides with Verily's transformation from a limited liability company to Verily Health Inc. (搜索), with Alphabet (搜索) relinquishing its controlling stake while maintaining a significant minority investment position. This restructuring provides the neutrality essential for deep integration within the heavily regulated healthcare industry, potentially eliminating partner hesitation about data sharing and collaboration with a Google-affiliated entity.
"Today is an important step in our mission to bring the promise of precision health to everyone," said Stephen Gillett, Chairman and CEO of Verily. "From research to care, our customers need solutions that bring the best of clinical and scientific rigor together with AI to deliver the next generation of healthcare - one that is as precise as it is personal."
AI Platform Strategy and Commercial Partnerships
Verily's core technology centers on harmonizing healthcare data and deploying actionable intelligence into research and care workflows. The company's Verily Pre platform helps life sciences companies and researchers organize fragmented healthcare records, genomic datasets, and wearable device information for AI analysis, aimed at discovering new biomarkers and accelerating clinical trials.
Recent commercial partnerships demonstrate growing market traction. The company announced a collaboration with Samsung (搜索)'s Galaxy Watch to help life sciences customers accelerate clinical research through biomarker development on the Pre platform. Additionally, Verily formed a strategic partnership with Salesforce (搜索), integrating the Verily Pre Platform with Agentforce Health to power enterprise precision health solutions.
Technology-Based Treatment Solutions
Beyond data platform capabilities, Verily develops direct treatment technologies including Lightpath, an AI-native care management platform for chronic diseases (搜索) such as diabetes (搜索). The company also offers Verily Me, a health companion application providing healthcare advice and recommendations to consumers.
These solutions build on Verily's strategic collaboration with UCHealth, the University of Colorado Anschutz (搜索), and RefinedScience (搜索), who are utilizing the Verily Pre platform for AI-powered research and care transformation.
Investment Strategy and Market Position
Series X Capital (搜索), established in collaboration with Google's X moonshot factory to scale breakthrough technologies, led the investment round. "We are extremely excited to lead this milestone round for Verily, as they drive commercial momentum as a leader in precision health," said Gideon Yu, Founder and Managing Partner of Series X Capital.
The funding enables Verily to transition into a financially disciplined and commercially viable enterprise capable of independent operation. Ruth Porat, President and Chief Investment Officer at Alphabet (搜索), noted that bringing in new investors alongside Alphabet's ongoing involvement enables Verily to scale its business to improve patient outcomes and lower healthcare delivery costs.
Healthcare Transformation Vision
Verily originally graduated from Google X (搜索) ten years ago as one of Alphabet (搜索)'s earliest "Other Bets," focusing on breakthrough science and health technology innovation. The company's current mission centers on transforming multimodal health data into insights, models, and actions that make healthcare more personalized, predictive, and precise.
"Partnering with Verily to bring a shared data framework to healthcare data, making it AI-ready, creates a generational opportunity for UCHealth and for medicine," said Richard Zane, MD, UCHealth Chief Medical and Innovation Officer. "This collaboration helps unlock the long-promised potential of personalized care, benefiting our patients and, ultimately, all patients."